Deprotection of sulfonamides using iodotrimethylsilane
摘要:
The deprotection of sulfonamides is achieved under neutral conditions by reaction with iodotrimethylsilane in acetonitrile at reflux. (C) 1999 Published by Elsevier Science Ltd. All rights reserved.
A mild and efficient procedure has been developed for the monosulfonylation of various amines using mesyl or tosyl chlorides in water at room temperature to afford the corresponding sulfonamides in high yields.
A segmented flow platform for on-demand medicinal chemistry and compound synthesis in oscillating droplets
作者:Ye-Jin Hwang、Connor W. Coley、Milad Abolhasani、Andreas L. Marzinzik、Guido Koch、Carsten Spanka、Hansjoerg Lehmann、Klavs F. Jensen
DOI:10.1039/c7cc03584e
日期:——
We report an automated flow chemistry platform that can efficiently perform a wide range of chemistries, including single/multi-phase and single/multi-step, with a reaction volume of just 14 μL. The breadth of compatible chemistries is successfully demonstrated and the desired products are characterized, isolated, and collected online by preparative HPLC/MS/ELSD.
我们报告了一个自动化的流动化学平台,该平台可以有效地执行各种化学反应,包括单相/多相和单步/多步,反应体积仅为14μL。通过制备型HPLC / MS / ELSD成功地证明了兼容化学的广度,并在线表征,分离和收集了所需的产品。
Sulfonamide compounds as cysteine protease inhibitors
申请人:Woo Soon H.
公开号:US20090233909A1
公开(公告)日:2009-09-17
The present invention is directed to compounds of formula (I) that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. Wherein R3 is -alkylene-SO2NR5R6.
The present invention is related to derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.
The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I
wherein X
1
, X
2
, X
3
, R
2
, R
3
, R
4
, R
5
, and Y are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.